Phase 1
Completed N=34
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Neoplasms · Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov NCT02862457 ↗
Enrolled (actual)
34
Serious AEs
29.4%
Results posted
Jan 2022
Primary outcomePrimary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) — 0; 0; 0; 1 Participants
Summary
This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors. The primary objective of the trial is to evaluate the safety and tolerability of epacadostat administered alone and in combination with pembrolizumab with and without chemotherapy.
With protocol amendment 02 (26-April-2019), treatment with epacadostat was stopped in the "Epacad+Pembro+Cisplatin+Pemetrexed", "Epacad+Pembro+Carboplatin+Pemetrexed", and "Epacad+Pembro+Carboplatin+Paclitaxel" study arms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) |
0; 0; 0; 1; 1; 2 | — |
| PRIMARY Number of Participants Who Experienced At Least One Adverse Event (AE) |
3; 2; 3; 6; 7; 6 | — |
| PRIMARY Number of Participants Who Discontinued Study Treatment Due to An Adverse Event (AE) |
0; 1; 0; 1; 0; 3 | — |
| SECONDARY Maximum Concentration (Cmax) of Epacadostat in Part A |
327; 1060; 269; 1100; 371; 852 | — |
| SECONDARY Time to Maximum Concentration (Tmax) of Epacadostat in Part A |
2.00; 2.00; 2.00; 2.00; 2.00; 2.00 | — |
| SECONDARY Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A |
855; 4250; 1060; 4670; 1260; 3950 | — |
| SECONDARY Trough Concentration (Ctrough) of Epacadostat in Part A |
NA; NA; NA; 87.7; NA; 106.0 | — |
| SECONDARY Terminal Half-Life (t1/2) of Epacadostat in Part A |
3.94; 2.55; 3.01; 2.82; 2.62; 3.77 | — |
| SECONDARY Maximum Concentration (Cmax) of Pembrolizumab in Part A Cycle 1 |
80.0; 73.8; 76.2 | — |
| SECONDARY Maximum Concentration (Cmax) of Pembrolizumab in Part B Cycle 1 |
73.8; 64.3; 65.3; 68.0 | — |
| SECONDARY Trough Concentration (Ctrough) of Pembrolizumab in Part A Cycles 1, 2, 4, 6, and 8 |
NA; NA; NA; 17.3; 17.9; 17.6 | — |
| SECONDARY Trough Concentration (Ctrough) of Pembrolizumab in Part B Cycles 1, 2, 4, 6, and 8 |
NA; NA; NA; NA; 16.6; 17.4 | — |
Eligibility Criteria
Inclusion Criteria
- For Part A: Has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.
- For Part B: Has a histologically-confirmed or cytologically confirmed diagnosis of non-small cell lung carcinoma (NSCLC) stage IIIB/IV, be naïve to systemic therapy, and have confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated. Cohort 1 and 2 must have a histological or cytological diagnosis of non-squamous cancer.
- Has at least one measurable lesion by computed tomography or magnetic resonance imaging per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
- Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Has a life expectancy of ≥3 months
- Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
- Women of childbearing potential and male participants must agree to use adequate contraception during the study through 120 days after the last dose of study medication
- For Part A: Has provided tissue for programmed cell death ligand 1 (PD-L1)/ Indoleamine 2,3-dioxygenase 1 (IDO1) expression evaluation from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. For Part B submission of tissue is optional.
Exclusion Criteria
- Has received prior therapy with an anti-Programmed cell death protein (PD)-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents (including ipilimumab or any other antibody/drug specifically targeting T-cell co-stimulation or checkpoint pathways), or IDO1 inhibitor
- Is currently participating or has participated in a study with an investigational compound or device within 4 weeks, or 5 times half-life of the investigational compound, whichever is longer, of initial dosing on this study
- For Part A: Has had chemotherapy, targeted small molecule therapy, radiotherapy, major surgery, or biological cancer therapy (including monoclonal antibodies) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study medication, or who has not recovered (≤ Grade 1 or baseline) from adverse events due to a previously administered treatment
- For Part B: Has received radiotherapy within 7 days of the first dose of trial treatment or radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study medication
- Is expected to require any other form of systemic or localized anti-neoplastic therapy while in study
- Has active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has symptomatic ascites or pleural effusion
- Has an active autoimmune disease that has required systemic treatment
- Is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 1 week prior to the first dose of study medication
- Has an active infection requiring systemic therapy
- Has history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease
- Has received a live vaccine within 4 weeks prior to the first dose of study medication
- Has a known hypersensitivity to the components of the trial treatment or another monoclonal antibody
- For Part B: Has a known sensitivity to any component of cisplatin, carboplatin, paclitaxel, or pemetrexed.
- For Part B: Is on chronic systemic steroids with the exception of use of bronchodilators, inhaled steroids, or local steroid injections
- For Part B cohort 1 and 2: Is unable to interrupt aspirin or other nonsteroidal ant-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
Data sourced from ClinicalTrials.gov (NCT02862457). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.